Roskamp Institute Articles Better Science. Real Discovery.

February 14, 2012

News:KEY CLINICAL TRIAL OF ALZHEIMER’S DISEASE DRUG BEGINS IN EUROPE DRUG DISCOVERED BY ROSKAMP INSTITUTE RESEARCH

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 12:46 pm
Contact: Steve Klindt
Tel: Tel:941-752-2949 x 390
Email: Sklindt@roskampinstitute.net

KEY CLINICAL TRIAL OF ALZHEIMER’S DISEASE DRUG BEGINS IN EUROPE DRUG DISCOVERED BY ROSKAMP INSTITUTE RESEARCH
SARASOTA, FL (Feb. 14) –

A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute (www.rfdn.org) in Sarasota. More than 500 Alzheimer’s patients in nine European countries will participate in the phase III trial designed to study the effectiveness of the medication.

“We believe that Nilvadipine blocks the production of amyloid proteins linked to Alzheimer’s disease,” said Roskamp Institute President and CEO Michael Mullan, M.D., Ph.D., who along with Associate Director Fiona Crawford, Ph.D., and Daniel Paris Ph.D. led the team that developed the drug. “That means Nilvadipine is aimed at addressing the actual disease, and not just the symptoms.”

A consortium of medical teams from nine European countries is meeting in Ireland this week to plan the US$10 million multicenter study. Phase III studies are usually the last step in the regulatory process before a drug can move into clinical practice. The consortium, called NILVAD for Nilvadipine/Alzheimer’s Disease, will involve participants from Ireland, England, Hungary, Greece, France, Sweden, Germany, Italy and the Netherlands.

The 500 participants, who have mild to moderate cognitive impairments, will begin the double-blind study this fall. Each participant will be followed for 18 months to see if the drug produces a change in cognitive abilities.

“We won’t cure Alzheimer’ disease without clinical trials,” said Crawford, who added that major pharmaceutical companies have not been able to come up with an effective drug. “Currently, there are only eight interventions underway in phase III trial, and it’s a tremendous achievement for a small research institute like ours to be part of the process.”

No Comments

No comments yet.

RSS feed for comments on this post.

Sorry, the comment form is closed at this time.

Powered by WordPress